CN102475741A - Traditional Chinese medicine compound and preparation method and application thereof - Google Patents
Traditional Chinese medicine compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN102475741A CN102475741A CN2011100026262A CN201110002626A CN102475741A CN 102475741 A CN102475741 A CN 102475741A CN 2011100026262 A CN2011100026262 A CN 2011100026262A CN 201110002626 A CN201110002626 A CN 201110002626A CN 102475741 A CN102475741 A CN 102475741A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- medicine compound
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 206010022000 influenza Diseases 0.000 claims abstract description 37
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 201000009240 nasopharyngitis Diseases 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 241000545442 Radix Species 0.000 claims description 8
- 241000207929 Scutellaria Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 241000213006 Angelica dahurica Species 0.000 abstract description 3
- 206010037660 Pyrexia Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 206010011224 Cough Diseases 0.000 abstract description 2
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 2
- 206010036790 Productive cough Diseases 0.000 abstract description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 240000004534 Scutellaria baicalensis Species 0.000 abstract description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract description 2
- 230000007803 itching Effects 0.000 abstract description 2
- 206010016326 Feeling cold Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract 1
- 201000007100 Pharyngitis Diseases 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 230000007012 clinical effect Effects 0.000 abstract 1
- 208000021760 high fever Diseases 0.000 abstract 1
- 210000004243 sweat Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 13
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 229960002194 oseltamivir phosphate Drugs 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 229940124579 cold medicine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 241000334154 Isatis tinctoria Species 0.000 description 2
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000035777 life prolongation Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206581 Gracilaria Species 0.000 description 1
- 241000382951 Hansenia forbesii Species 0.000 description 1
- 241000533388 Hansenia weberbaueriana Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000382362 Persicaria tinctoria Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 1
- 244000296102 Selinum monnieri Species 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZICQBHNGXDOVJF-UHFFFAOYSA-N diamantane Chemical compound C1C2C3CC(C4)CC2C2C4C3CC1C2 ZICQBHNGXDOVJF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013390 scatchard method Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine compound preparations for preventing or treating cold. The traditional Chinese medicine compound of the invention comprises the following traditional Chinese medicine raw materials in parts by weight: 1-40 parts of notopterygium root, 1-20 parts of angelica dahurica, 1-50 parts of folium isatidis, 1-50 parts of scutellaria baicalensis, 1-30 parts of radix sophorae flavescentis and 1-30 parts of fructus cnidii. The traditional Chinese medicine compound preparation integrates the effects of dispelling the evil by pungent and warm, relieving exterior syndrome by pungent and cool, and clearing away heat and toxic materials, is different from the traditional single agents for relieving exterior syndrome and clearing heat, advocates that the defensive exterior syndrome firstly sweats and expels evil, advocates the combination of cold and warm, has good antipyretic effect, is clinically used for treating the symptoms of influenza and common cold, and has obvious clinical effects of fever or high fever, chilliness, muscle ache, nasal obstruction and running nose, sore throat and itching throat, cough and expectoration, thin white or thin yellow tongue red fur and the like.
Description
Technical field
The invention belongs to the compound Chinese medicinal preparation technical field that is used to prevent or treat influenza and common cold.
Background technology
Clinically flu is divided into influenza and common cold two big classes.
Influenza (influenza is called for short influenza) is the ARI that influenza virus causes, typical clinical symptoms is: anxious hyperpyrexia, whole body pain, the remarkable weak and slight respiratory symptom of rising.Influenza is one of infectious disease occurred frequently in the world always, and the population in the annual whole world about 10% infects influenza.Only 20th century, just break out 3 global flu outbreaks, caused several hundred million people to infect.Be very popular and cause the attention of various countries to influenza again in the influenza A H1N1 whole world in 2009.
The major measure of flu-prevention is a vaccine virus immunization.But vaccine only has preventive effect to known influenza virus sub-strain, and invalid for the new type influenza virus that is produced by antigenic drift or antigenicity conversion.Because the antigenic variation ability of influenza virus is strong; Antigenic variation (is exactly the novel variation strain of influenza virus like first type HIN1 influenza virus) takes place in its surface glycoprotein (mainly being hemagglutinin HA and neuraminidase NA) easily; Make vaccine not high to the protective rate of Susceptible population, preventive effect is not high.
The main method of treatment influenza is a pharmacotherapy.At present anti-influenza virus medicament mainly is M2 inhibitors of ion channels (amantadine and rimantadine) or viral neuraminidase inhibitor (Oseltamivir (oseltamivir phosphate capsule) and zanamivir), but has all limited its clinical practice owing to the drug resistance of its intrinsic toxicity and prolonged application.Diamantane (obsolete) amine medicine insomnia, distractibility and unstrung side effect can occur taking the back several hours, the more important thing is that it is prone to the strain that develops immunity to drugs when clinical practice.For neuraminidase inhibitor class medicine, be example with the oseltamivir phosphate capsule, its main adverse reaction is digestive tract, respiratory system, central nervous system's side effect; Also mention in the amended oseltamivir phosphate capsule description of FDA in 2007, " mentally deranged, dystropy appears in taking the influenza patient of oseltamivir phosphate capsule and the untoward reaction that causes injuring, and some fatal cases "; Seasonal influenza virus oseltamivir phosphate capsule persister has also appearred recently.
Because influenza virus vaccine and existing antiviral drugs can not be tackled the variation of influenza and the treatment demand of clinical Cavity in Critical Patients, therefore, demand seeking new Tamiflu urgently.
Influenza is called " influenza " in Chinese medicine, belong to " epidemic disease evil (being infectious disease) ", with the variation of 4 o'clock weathers confidential relation is arranged.In the process that fights back the disease for a long time, Chinese medicine is accumulating rich experience aspect treatment influenza, the flu, how from the traditional Chinese medicine of China, to excavate the effective influenza, the cold medicine that make new advances and seems extremely important.Many researchs show; Chinese medicine compound not only has advantages such as drug resistance is low, few side effects; And have suppress virus replication, stop pathological changes caused by virus, regulate immunologic function, improve pulmonary circulation, comprehensive effect such as antalgic and inflammation relieving, have special advantages and vast potential for future development aspect influenza, the flu preventing and treating.Therefore, new influenza, the cold medicine of exploitation is an important channel from Chinese medicine compound.
Summary of the invention
The objective of the invention is to overcome the weak point of existing treatment influenza, cold medicine; A kind of compound Chinese medicinal preparation that prevents and/or treats influenza and common cold sign is provided; Through pharmacodynamic experiment and clinical case research checking; This medicine is primarily aimed at influenza, flu, and antivirus action is arranged, and it is obvious with analgesic effect to bring down a fever.
Another object of the present invention provides the application of above-mentioned compound Chinese medicinal preparation in preventing and/or treating influenza and catching a cold.
Inventor herein's traditional Chinese medical science great master professor Yan Dexin thinks that the pathogenesis of respiratory system acute infectious diseases such as influenza is attacked for " cold epidemic disease " is outer, and Wei Yang is by strongly fragrant; Inhibited pulmonary QI; The cause of disease is for cold, and disease is pressed from both sides heat (wind heat disease), and it is main that this type of disease treatment should reach heresy with suffering temperature lung qi dispersing; Using corrigent has been founded the novelty academic thought that acute calenture is controlled from " trembling with fear " opinion with clearing up internal heat by using drugs of bitter in taste and cold in nature.
For reaching above-mentioned purpose, the technical scheme that the present invention takes is following:
A kind of Chinese medicine compound, the weight proportion of its raw material of Chinese medicine is: Rhizoma Et Radix Notopterygii 1-40 part, Radix Angelicae Dahuricae 1-20 part, Folium Isatidis 1-50 part, Radix Scutellariae 1-50 part, Radix Sophorae Flavescentis 1-30 part, Fructus Cnidii 1-30 part.
Above-mentioned Chinese medicine compound, preferred scheme is: Rhizoma Et Radix Notopterygii 4-35 part, Radix Angelicae Dahuricae 2-15 part, Folium Isatidis 5-40 part, Radix Scutellariae 5-40 part, Radix Sophorae Flavescentis 3-25 part, Fructus Cnidii 2-25 part.Most preferably: 12 parts of Rhizoma Et Radix Notopterygiis, 6 parts of the Radixs Angelicae Dahuricae, 18 parts of Folium Isatidiss, 18 parts of Radix Scutellariaes, 6 parts of Radix Sophorae Flavescentiss, 6 parts of Fructus Cnidiis.
Above weight portion can manufacture preparation with gram, kilogram, ton or other unit of weights, as: Rhizoma Et Radix Notopterygii 120g, Radix Angelicae Dahuricae 60g, Folium Isatidis 180g, Radix Scutellariae 180g, Radix Sophorae Flavescentis 60g, Fructus Cnidii 60g.Can be made into the pharmaceutical preparation of 500-2000 agent, can be made into 1000 capsules like capsule, tablet can be made into 1000 tablets of tablets; Wherein contain in each capsules or each sheet: Rhizoma Et Radix Notopterygii 0.12g, Radix Angelicae Dahuricae 0.6g, Folium Isatidis 0.18g; Radix Scutellariae 0.18g, Radix Sophorae Flavescentis 0.6g, Fructus Cnidii 0.6g.
Rhizoma Et Radix Notopterygii, latin name: Notopterygium incisum Ting ex H.T.Chang or Notopterygium franchetii H.de Boiss.Another name: river Qiang, silkworm Qiang, RHIZOMA SEU RADIX NOTOPTERYGII, RHIZOMA SEU RADIX NOTOPTERYGII.Medicinal part: rhizome and root.
The Radix Angelicae Dahuricae, latin name: Angelica dahurica (Fisch.ex Hoffm.) Benth.et Hook.f. or Angelica dahurica (Fisch.ex Hoffm.) Benth.et Hook.f.var.formosana (Boiss.) Shan et Yuan.Alias: Fu Gracilaria, Zefen, white Chen, Hong Angelica.Medicinal part: root.
Folium Isatidis, latin name: Isatis indigotica Fort. another name: Folium Isatidis, roadside Folium Isatidis, Isatis indigotica Fort. leaf, Folium acanthaceous indigo, careless Folium Isatidis, polygonum tinctorium ait. leaf etc.Medicinal part: leaf.
Radix Scutellariae, latin name: Scutellaria baicalensis Georgi.Another name: Radix Scutellariae, soil
Gold teaRoot.Medicinal part: root.
Radix Sophorae Flavescentis, latin name: Sophora flavescens Ait. another name: bitter bone, river ginseng, phoenix claw, cattle ginseng.Medicinal part: root.
Fructus Cnidii, latin name: Cnidium monnieri (L.) Cuss. another name: wild Fructus Foeniculi, Daucus carota L., Serpentis rice, She Li.Medicinal part: mature fruit.
One of method for preparing of above-mentioned Chinese medicine compound comprises the following steps:
(1) prepares each crude drug by weight ratio;
(2) with ready crude drug decocte with water, be condensed into extractum after the filtration decoction liquor, add the ethanol precipitate with ethanol, reclaim ethanol and also be concentrated in right amount, must have the extractum of active constituents of medicine.
Above-mentioned step (2), preferred scheme is decocte with water 1-3 time, each 0.5-1.5 hour, merge decoction liquor, cross and filter filtrating, be condensed into the extractum that proportion is 1.0-1.3 after the filtration decoction liquor, add 90-95% ethanol precipitate with ethanol.
Chinese medicine compound of the present invention also can adopt in the existing pharmaceutical field other conventional method preparation, can add various pharmaceutically acceptable carriers when needing, and can be made into any pharmaceutically acceptable dosage form.Described carrier comprises the conventional diluent of pharmaceutical field, excipient, binding agent, disintegrating agent, wetting agent, lubricant, surfactant etc., as: starch, sucrose, dextrin, lactose, magnesium stearate, cellulose family and derivant thereof, gelatin, polyvinylpyrrolidone etc.Traditional Chinese compound medicine of the present invention is preferably processed oral formulations, as: granule, tablet, capsule, ointment, oral liquid, soft extract, pill etc.; Also can be made into injection, as: liquid drugs injection, freeze-dried powder, aseptic powder injection, transfusion etc.
Compound Chinese medicinal preparation of the present invention, its active ingredient be by Rhizoma Et Radix Notopterygii, the Radix Angelicae Dahuricae; Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis; Fructus Cnidii 6 flavor Chinese medicines are processed, and full side integrates that hot temperature is dispersed, relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, heat-clearing and toxic substances removing, is different from single in the past agent of separating the harmony in the exterior heat clearing away; Advocate to defend the first antiperspirant expelling pathogenic factors from the exterior of table, advocate using medicines of both cold and hot natures simultaneously, it is effective to bring down a fever; The clinical sign that is used to treat influenza and common cold, disease are seen heating or hyperpyrexia, aversion to cold, muscular soreness, nasal obstruction watery nasal discharge, pharyngalgia itching throat, cough and expectoration, red tongue with thin fur is white or BOHUANG etc., and clinical effectiveness is remarkable.
The specific embodiment
In order to understand the present invention better, below technological feasibility of the present invention is described, is proved pharmacology result of the present invention through Test Example through embodiment.
Embodiment 1: the preparation of the active component of medicine of the present invention
(1) takes by weighing raw material of Chinese medicine (is example with 10 times of material proportional quantities) by following weight proportion: 120 parts of Rhizoma Et Radix Notopterygiis, 60 parts of the Radixs Angelicae Dahuricae, 180 parts of Folium Isatidiss, 180 parts of Radix Scutellariaes, 60 parts of Radix Sophorae Flavescentiss, 60 parts of Fructus Cnidiis.
(2) take by weighing the Rhizoma Et Radix Notopterygii of above-mentioned weight proportion, the Radix Angelicae Dahuricae, Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis, Fructus Cnidii adds 10 times of water gagings and decocted 1 hour, filters; Filtering residue adds 8 times of water gagings and decocted 1 hour, filters.Merging filtrate, being concentrated into relative density is 1.25, adding 95% ethanol, to make solution contain alcohol amount be 70%, precipitate with ethanol 24 hours.Reclaim ethanol, be concentrated into proportion and be 1.30 extractum, make extractum, be the active component of this invention medicine.
Embodiment 2: the preparation of the active component of medicine of the present invention
(1) takes by weighing raw material of Chinese medicine (is example with 10 times of material proportional quantities) by following weight proportion: 100 parts of Rhizoma Et Radix Notopterygiis, 50 parts of the Radixs Angelicae Dahuricae, 150 parts of Folium Isatidiss, 150 parts of Radix Scutellariaes, 50 parts of Radix Sophorae Flavescentiss, 50 parts of Fructus Cnidiis.
(2) take by weighing the Rhizoma Et Radix Notopterygii of above-mentioned weight proportion, the Radix Angelicae Dahuricae, Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis, Fructus Cnidii, preparation process makes extractum with embodiment 1, must be somebody's turn to do the active component of invention medicine.
Embodiment 3: the preparation of the active component of medicine of the present invention
(1) takes by weighing raw material of Chinese medicine (is example with 10 times of material proportional quantities) by following weight proportion: 400 parts of Rhizoma Et Radix Notopterygiis, 200 parts of the Radixs Angelicae Dahuricae, 500 parts of Folium Isatidiss, 500 parts of Radix Scutellariaes, 200 parts of Radix Sophorae Flavescentiss, 200 parts of Fructus Cnidiis.
(2) take by weighing the Rhizoma Et Radix Notopterygii of above-mentioned weight proportion, the Radix Angelicae Dahuricae, Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis, Fructus Cnidii, preparation process makes extractum with embodiment 1, must be somebody's turn to do the active component of invention medicine.
Embodiment 4: the preparation of the active component of medicine of the present invention
(1) takes by weighing raw material of Chinese medicine (is example with 10 times of material proportional quantities) by following weight proportion: 200 parts of Rhizoma Et Radix Notopterygiis, 100 parts of the Radixs Angelicae Dahuricae, 250 parts of Folium Isatidiss, 250 parts of Radix Scutellariaes, 100 parts of Radix Sophorae Flavescentiss, 100 parts of Fructus Cnidiis.
(2) take by weighing the Rhizoma Et Radix Notopterygii of above-mentioned weight proportion, the Radix Angelicae Dahuricae, Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis, Fructus Cnidii, preparation process makes extractum with embodiment 1, must be somebody's turn to do the active component of invention medicine.
The preparation of the active component of embodiment 5 medicines of the present invention
(1) takes by weighing raw material of Chinese medicine (is example with 10 times of material proportional quantities) by following weight proportion: 40 parts of Rhizoma Et Radix Notopterygiis, 20 parts of the Radixs Angelicae Dahuricae, 50 parts of Folium Isatidiss, 50 parts of Radix Scutellariaes, 30 parts of Radix Sophorae Flavescentiss, 20 parts of Fructus Cnidiis.
(2) take by weighing the Rhizoma Et Radix Notopterygii of above-mentioned weight proportion, the Radix Angelicae Dahuricae, Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis, Fructus Cnidii, preparation process makes extractum with embodiment 1, must be somebody's turn to do the active component of invention medicine.
The preparation of the active component of embodiment 6 medicines of the present invention
(1) takes by weighing raw material of Chinese medicine (is example with 10 times of material proportional quantities) by following weight proportion: 350 parts of Rhizoma Et Radix Notopterygiis, 150 parts of the Radixs Angelicae Dahuricae, 400 parts of Folium Isatidiss, 400 parts of Radix Scutellariaes, 250 parts of Radix Sophorae Flavescentiss, 250 parts of Fructus Cnidiis.
(2) take by weighing the Rhizoma Et Radix Notopterygii of above-mentioned weight proportion, the Radix Angelicae Dahuricae, Folium Isatidis, Radix Scutellariae, Radix Sophorae Flavescentis, Fructus Cnidii, preparation process makes extractum with embodiment 1, must be somebody's turn to do the active component of invention medicine.
Embodiment 7: the preparation of granule
Get 60 parts of the active components that prepare by method among the embodiment 1, with 120 parts of sucrose, 80 parts in dextrin, mixing.Add 75% ethanol mixing again, process soft material, granulate with 14 mesh sieves, place 75 ℃ of dry backs in 12 mesh sieve granulate, behind the mixing, packing promptly gets granule.
Embodiment 8: the preparation of tablet
(1) get 60 parts of the active components that prepare by method among the embodiment 1, add 40 parts in dextrin, mix thoroughly, vacuum drying (40-60 ℃) is ground into fine powder (crossing 100 mesh sieves) after do.
(2) get the said medicine fine powder, mix with 60 parts of dextrin and 30 parts of starch again, add 5 part of 10% starch slurry and process soft material, granulate, place 70 ℃ of dry backs in 12 mesh sieve granulate with 14 mesh sieves, add 0.8 part of magnesium stearate mixing after, tabletting promptly gets tablet.
Embodiment 9: the preparation of capsule
(1) get 60 parts of the active components that prepare by method among the embodiment 1, add 40 parts in dextrin, mix thoroughly, vacuum drying (40-60 ℃) is ground into fine powder (crossing 100 mesh sieves) after do.
(2) get the said medicine fine powder, mix with 60 parts of dextrin and 30 parts of starch, add 5 part of 10% starch slurry and process soft material, granulate with 14 mesh sieves, place 80 ℃ of dry backs in 12 mesh sieve granulate, behind the mixing, the snap fit capsule of packing into promptly gets capsule.
Embodiment 10: the preparation of oral liquid
Get the active component 60ml for preparing by method among the embodiment 1, add an amount of sodium benzoate solution, add the 500ml purified water, filter.Add purified water to 1000ml, promptly get oral liquid.
Test Example 1
Get the active component of the medicine of the present invention for preparing among the embodiment 1, drying is ground, and obtains the sepia fine powder.As the experiment medicine, carry out the resisiting influenza virus test of pesticide effectiveness in the body with this fine powder, method and result are following:
(1) to mice influenza inhibition test
1, method
Get mice, random packet, 6 every group, male and female half and half, experiment is established:
(1) normal control group: normal saline, 0.2mL/10g/d * 6
(2) virus control group
(3) positive controls
Ribavirin: 0.1g/kg dose groups
Oseltamivir phosphate capsule:
1. 72mg/kg dose groups: 3mg/mL oseltamivir phosphate capsule oral liquid, each administration 0.5mL/20g mice, a twice-daily, administration is 7 days altogether
2. 24mg/kg dose groups: 1mg/mL oseltamivir phosphate capsule oral liquid, each administration 0.5mL/20g mice, a twice-daily, administration is 7 days altogether
3. 8mg/kg dose groups: 0.33mg/mL oseltamivir phosphate capsule oral liquid, each administration 0.5mL/20g mice, a twice-daily, administration is 7 days altogether
4. 2.6mg/kg dose groups: 0.11mg/mL oseltamivir phosphate capsule oral liquid, each administration 0.5mL/20g mice, a twice-daily, administration is 7 days altogether
(4) administration group:
1. 2.88g/kg dose groups: 6% receives examination group suspension, each administration 0.5mL/20g mice, and a twice-daily, administration is 7 days altogether
2. 960mg/kg dose groups: 2% receives examination group suspension, each administration 0.5mL/20g mice, and a twice-daily, administration is 7 days altogether
3. 320mg/kg dose groups: 0.67% receives examination group suspension, each administration 0.5mL/20g mice, and a twice-daily, administration is 7 days altogether
4. 107mg/kg dose groups: 0.22% receives examination group suspension, each administration 0.5mL/20g mice, and a twice-daily, administration is 7 days altogether
The equal collunarium of mice infects 8～10LD except that the normal control group
50Virus quantity promptly begins oral administration after 2 hours, every day, secondary was total to administration 7 days, observed for two weeks, and the record death toll takes statistics and learns processing, and calculating P value is average life day of calculating and life prolongation % also;
2, result of the test
This Test Example invention medicine adopts Stat View Ver 5.01 SASInstitute Inc softwares to carry out Mann-Whitney check and statistical procedures to the influence of mice survival natural law.Through test, the result shows with the virus control group and compares that administration 960mg/kg, 320mg/kg, this Test Example of 107mg/kg invention medicine suppress mice influenza FM1, and life prolongs 130%, 83.8% and 20.6%.Calculate through Scat chard method again, the male mice influenza is suppressed median effective dose ED
50Be 265.6mg/kg, to female mice ED
50Be 169.3mg/kg, male and female hybrid ED
50Be 218.3mg/kg.
(2) to the influence of mouse lung pathological changes
1, method
Get mice, random packet, 6 every group, male and female half and half; Grouping and administration number of times and the same test of infective virus amount, once a day, the 4th day dissection mice after the infection administration; Observe mouse lung pathological changes situation, compare pneumonopathy with the virus control group and become %, and calculate medicine mouse lung pathological changes suppression ratio %.And get the detection that lung carries out viral power (titre).
2, result of the test
This Test Example invention medicine adopts SPSS 11.5for Windows software to be χ to the influence of mouse lung pathological changes
2Check and statistical procedures.Through test, the result shows with the virus control group and compares that administration 960mg/kg, 320mg/kg, 107mg/kg mouse lung pathological changes alleviate rate 67.7%, 28.6% and 24.7%.The virus titer suppression ratio is 68.75%, 33.3% and 25%.
Medicine of the present invention has the obvious suppression effect to mice influenza FM1 in vivo; Infecting mouse life is prolonged; Alleviate mouse lung pathological changes rate, pulmonary epithelial cells is had protective effect, alleviate injury of lung; Suppress the mice virus titer.Compare with oseltamivir phosphate capsule, according to adult's RD, resisiting influenza virus test aspect comprises alleviating of life prolongation and pulmonary lesion in vivo, and effect is approaching.
Claims (9)
1. Chinese medicine compound, the weight proportion of its raw material of Chinese medicine is: Rhizoma Et Radix Notopterygii 1-40 part, Radix Angelicae Dahuricae 1-20 part, Folium Isatidis 1-50 part, Radix Scutellariae 1-50 part, Radix Sophorae Flavescentis 1-30 part, Fructus Cnidii 1-30 part.
2. Chinese medicine compound as claimed in claim 1 is characterized in that: the weight proportion of raw material of Chinese medicine is: Rhizoma Et Radix Notopterygii 4-35 part, Radix Angelicae Dahuricae 2-15 part, Folium Isatidis 5-40 part, Radix Scutellariae 5-40 part, Radix Sophorae Flavescentis 3-25 part, Fructus Cnidii 2-25 part.
3. Chinese medicine compound as claimed in claim 2 is characterized in that: the weight proportion of raw material of Chinese medicine is: 12 parts of Rhizoma Et Radix Notopterygiis, 6 parts of the Radixs Angelicae Dahuricae, 18 parts of Folium Isatidiss, 18 parts of Radix Scutellariaes, 6 parts of Radix Sophorae Flavescentiss, 6 parts of Fructus Cnidiis.
4. the method for preparing of the described arbitrary Chinese medicine compound of claim 1-3, it comprises the following steps:
(1) prepares each crude drug by weight ratio;
(2) with ready crude drug decocte with water, be condensed into extractum after the filtration decoction liquor, add the ethanol precipitate with ethanol, reclaim ethanol and also be concentrated in right amount, must have the extractum of active constituents of medicine.
5. the method for preparing of Chinese medicine compound as claimed in claim 4 is characterized in that: step (2) decocte with water 1-3 time, each 0.5-1.5 hour; Merge decoction liquor; Cross and filter filtrating, be condensed into the extractum that proportion is 1.0-1.3 after the filtration decoction liquor, add 90-95% ethanol precipitate with ethanol.
6. compound Chinese medicinal preparation, its effective ingredient is the described arbitrary Chinese medicine compound of claim 1-3, its dosage form is any pharmaceutically said dosage form.
7. compound Chinese medicinal preparation as claimed in claim 6 is characterized in that: its dosage form is granule, tablet, capsule, powder, pill, syrup, oral liquid or injection.
8. the application of the described arbitrary Chinese medicine compound of claim 1-3 in preventing and/or treating influenza and common cold drug.
9. claim 6 or 7 application of described compound Chinese medicinal preparation in preventing and/or treating influenza and common cold drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100026262A CN102475741A (en) | 2011-01-07 | 2011-01-07 | Traditional Chinese medicine compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100026262A CN102475741A (en) | 2011-01-07 | 2011-01-07 | Traditional Chinese medicine compound and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102475741A true CN102475741A (en) | 2012-05-30 |
Family
ID=46088599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100026262A Pending CN102475741A (en) | 2011-01-07 | 2011-01-07 | Traditional Chinese medicine compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102475741A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1035954A (en) * | 1988-03-21 | 1989-10-04 | 魏希诚 | Fluid for seasonal illness |
-
2011
- 2011-01-07 CN CN2011100026262A patent/CN102475741A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1035954A (en) * | 1988-03-21 | 1989-10-04 | 魏希诚 | Fluid for seasonal illness |
Non-Patent Citations (1)
| Title |
|---|
| 季蓓等: "轻可去实刍议", 《中医杂志》, vol. 50, no. 11, 17 November 2009 (2009-11-17), pages 1050 - 1051 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018210228A1 (en) | Antiviral traditional chinese medicine composition, preparation method therefor and application thereof | |
| US11998583B2 (en) | Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof | |
| CN102319294A (en) | Double-vanilla preparation and preparation method thereof | |
| CN102552512B (en) | Traditional Chinese medicine used for treating hepatitis B | |
| CN103285230B (en) | Pharmaceutical composition for treating pharyngitis and preparation method thereof | |
| CN110193061B (en) | Preparation and application of traditional Chinese medicine granules for treating or preventing children influenza virus infection | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN101791338B (en) | Anti-influenza medicine, preparation method and application thereof | |
| CN101773532B (en) | Carpesium abrotanoides total terpene lactones extract | |
| CN103356728B (en) | Pharmaceutical composition, preparation method thereof, preparations thereof and application thereof | |
| CN106606592A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN102475741A (en) | Traditional Chinese medicine compound and preparation method and application thereof | |
| CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN104147270A (en) | Traditional Chinese medicine for treating acute hepatitis | |
| CN103585291B (en) | Application of herba delphinii extract in preparation of drugs treating AIDS | |
| CN103585212B (en) | The application of Dorema ammoniacum resin extract in preparation treatment AIDS-treating medicine | |
| CN103585222B (en) | The application of a kind of Ligularia purdomii extract in preparation treatment AIDS-treating medicine | |
| CN105641168A (en) | Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine | |
| CN103585259B (en) | The application of a kind of Mucuna birdwoodiana Tutcher extract in preparation treatment AIDS-treating medicine | |
| CN105412407A (en) | Traditional Chinese medicine composition for preventing and curing flu as well as preparation method and application thereof | |
| CN103585239B (en) | A kind of preparation method of Boraginaceae extract and application thereof | |
| CN103585219B (en) | The application of a kind of Altay Heteropappus hispidus (Thunb.) Less.-Aster hispidus Thunb． extract in preparation treatment AIDS-treating medicine | |
| CN103585197B (en) | The application of mesh Herba Lepisori Thunbergiani extract in preparation treatment AIDS-treating medicine | |
| CN103585236B (en) | The application of Radix Berberidis Amurensis berry extract in preparation treatment AIDS-treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120530 |